← All trials
NCT06265012
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 5, 2024
- Primary completion
- Apr 17, 2024
- Completion date
- Sep 16, 2024
- First posted
- Feb 20, 2024
- Last posted
- Feb 22, 2024
- Enrollment
- 36
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Public Health Vaccines LLCLead sponsor
- Department of Health and Human ServicesCollaborator
- Public Health Vaccines LLCOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.